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Malaria-speciﬁc antibody responses in children often appear to be short-lived but the mechanisms underlying
this phenomenon are not well understood. In this study, we investigated the relationship between the B-cell
activating factor (BAFF) and its receptors expressed on B cells with antibody responses during and after acute
malaria in children. Our results demonstrate that BAFF plasma levels increased during acute malarial disease
and reﬂected disease severity. The expression proﬁles for BAFF receptors on B cells agreed with rapid activation
and differentiation of a proportion of B cells to plasma cells. However, BAFF receptor (BAFF-R) expression was
reduced on all peripheral blood B cells during acute infection, but those children withthe highest level of BAFF-
R expression onB cells maintained schizont-speciﬁcimmunoglobin G (IgG) over a period of 4 months, indicating
that dysregulation of BAFF-R expression on B cells may contribute to short-lived antibody responses to malarial
antigens in children. In summary, this study suggests a potential role for BAFF during malaria disease, both as
a marker for disease severity and in shaping the differentiation pattern of antigen-speciﬁc B cells.
Children living in malaria-endemic areas in sub–
Saharan Africa are repeatedly infected with the parasite
Plasmodium falciparum and bear the main burden of
clinical and often life-threatening severe malarial dis-
ease. Clinical immunity to the blood stage of infection is
acquiredover time, and eventually protectsfrom clinical
symptoms but not from infection per se. There is no
doubt that antibodies play a critical role in protection
from clinical malaria, since the transfer of gamma
globulins prepared from immune serum of adults into
children with acute malaria resulted in resolution of
clinical disease [1, 2]. Many P. falciparum blood-stage
antigens are either polymorphic and/or undergo clonal
antigenic variation [3], and protection from clinical
disease hasbeen associated with the ability to respond to
wide variety of polymorphic or variant antigens [4–6].
However, several studies reported that antibody re-
sponses to some malarial antigens are short-lived and
can be detected only in the presence of parasites, sug-
gesting a defect in the development and or maintenance
of long-lived plasma cells [7–9].
Upon activation, B cells can differentiate into short-
lived plasma cells [10] or undergo germinal center mat-
uration, emerging as long-lived plasma cells (LLPCs) or
long-lived memory B cells (MBCs). Upon reactivation,
the latter rapidly differentiate into antibody secreting
plasma cells (ASCs) [11]. Only a few studies have ana-
lyzed B-cell responses to malarial antigens in exposed
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tibodies are detectable in a proportion of infected individuals
[12–14]. In addition, some studies reported altered distribution
of B-cell subsets in children and adults living in malaria-endemic
areas, such as an increase in the percentage of transitional B cells,
CD38
1IgD
2 MBCs [15], and atypical MBCs [13], suggesting
some dysfunction of the B-cell compartment during acute and
chronic P. falciparum malaria infection.
The ‘‘B-cell activating factor belonging to the tumor necrosis
family’’ (BAFF) is a cytokine critical for the survival and differ-
entiation of B cells throughout their developmental stages. It is
expressed as a transmembrane protein on the surface of neu-
trophils, monocyte/macrophages, and dendritic cells [16, 17], but
can be cleaved from the membrane by furin convertase [17, 18].
Both the membrane-bound [16]a n ds o l u b l ef o rm sa r ea c t i v e[ 18]
and constitutively expressed in steady state. In humans, BAFF is
essential for T-cell–dependent and –independent class switch
recombination [19] and supports the survival of plasmablasts,
plasma cells [20], and MBCs [21]. It has been suggested that the
accumulation of plasma cells after an acute infection is a result of
the effect of BAFF on both plasma-cell differentiation and sur-
vival.
Three receptors for BAFF are differentially expressed during
B-cell differentiation [22]. The BAFF receptor (BAFF-R) is the
sole receptor mediating homeostatic B-cell survival. Its expres-
sion increases upon B-cell activation, but is replaced by B-cell
maturation antigen (BCMA) with differentiation into LLPCs.
The transmembrane activator and calcium modulator and cy-
clophilin ligand interactor (TACI) is constitutively expressed on
a proportion of MBCs and can be induced on activated B cells.
TACI can act as a negative regulator of B-cell homeostasis by
blocking terminal B-cell differentiation, yet may be important
for plasma cell differentiation because TACI-deﬁcient humans
suffer from hypergammaglobulinemia of all subclasses [22].
The expression of BAFF is increased in the presence of type I
and II interferons (IFNs) and interleukin 10 (IL-10), in auto-
immune conditions [23–25], and infectious diseases. Elevated
levels of BAFF have been observed in human immunodeﬁciency
virus (HIV)–infected individuals [26] and correlated with disease
progression [27] and levels of auto-antibodies [26]. In addition,
reduced BAFF-receptor expression on B cells has been associated
with reduced B-cell survival in HIV viremic patients [28]. By
contrast, BAFF plasma levels have been positively associated with
B-cell proliferation in hepatitis C virus infections [29]. A recent
study reported that hemozoin and soluble P. falciparum antigen
inducesecretion ofBAFFbymonocytesaswellasupregulationof
BAFF-R on, proliferation, and plasma-blast differentiation of B
cells in vitro [30].
In this paper, we have investigated whether BAFF and ex-
pression of BAFF-R on B cells could be part of the inﬂammatory
response associated with malaria and thus may offer some
explanation for the altered B-cell populations and apparent
short-lived nature of some antibody responses. We report here
that BAFF plasma levels increased during acute disease and re-
ﬂected disease severity. The expression proﬁles for BAFF-R on B
cells indicated rapid activation and differentiation of a pro-
portion of B cells to plasma blasts following infection. However
BAFF-R expression was reduced on all peripheral blood B cells
but directly correlated with schizont-speciﬁc immunoglobin G
(IgG) after the acute malaria episode.
PATIENTS, MATERIALS, AND METHODS
Study Population and Blood Collection
The study was carried out at the Kiliﬁ District Hospital (KDH)
situated 60 km north of Mombasa. Malariometric parameters
for this area have been described elsewhere [31, 32]. Children
undertheageof10yearspresentingattheKiliﬁDistrictHospital
(KDH) with a primary diagnosis of malaria were recruited be-
tween 2006 and 2008 after their guardian provided informed
written consent. Children were classiﬁed into those with mild
disease (fever .37.5C and a blood ﬁlm positive for P. falciparum
parasites), those with nonsevere malaria (admitted to KDH but
no signs of severe life-threatening disease), and those with severe
malaria (admitted to KDH and suffering from at least 1 severe
syndrome: impaired consciousness [Blantyre Coma Score ,5],
severe respiratory distress or severe anemia [hemoglobin
,5 g/L] [33]). At presentation, 3 mL blood was drawn and
children invited to donate additional 5 mL blood samples 4 and
16 weeks after admission. During follow-up visits, children
were clinically examined and treated if necessary. A 5 mL ve-
nous blood sample was obtained from healthy children ,10
years of age during the cross-sectional survey of children under
active surveillance for malaria in May 2008.
All blood samples were centrifuged, plasma removed, and
stored at 280C for later cytokine detection. Peripheral blood
mononuclear cells (PBMCs) were obtained after Ficoll-Paque
gradient centrifugation using Lymphoprep (Nycomed, Oslo,
Norway). PBMCs were washed, counted, and stored in liquid
nitrogen until use.
The study was approved by the Kenyan Medical Research
Institute, Ethical Review Committee under the SSC protocol
number 1131, and the Oxford Tropical Research Ethics Com-
mittee, protocol number 30-06.
Flow Cytometry
PBMCs were thawed and viable cells counted using trypan blue
exclusion. The expression of BAFF-R on B cells was determined
by staining 1 3 10
5 viable PBMCs with CD19-ECD, CD27-PC5
(Beckman Coulter), CD38-PECY7 (eBiosciences), and either
CD237-FITC (BAFF-R/BR3), CD267-PE (BD Biosciences), or
polyclonal antihuman BCMA-PE (R&D Systems). Cells were
incubated with antibody cocktails for 30 minutes in the dark,
washed, and acquired on a CyAN ADP analyzer (Beckman
Coulter). Data were analyzed using FlowJo Africa (kindly donated
BAFF in Malaria d JID 2011:204 (15 September) d 963by FlowJo Treestar). The absolute number of B cells was cal-
culated using differential whole blood counts.
Enzyme-Linked Immunosorbent Assay
IL-10, interferon c (IFNc), and BAFF levels in plasma were
detected using OptEIA Human IL-10 enzyme-linked immuno-
sorbent assay (ELISA), OptEIA Human IFNc ELISA set (BD
Biosciences), and Quantikine Human BAFF Immunoassay kit
(R&D systems), respectively, according to the manufacturers’
instructions. Schizont-speciﬁc antibodies were measured as de-
scribed previously [34]. For the determination of total im-
munoglobin M (IgM) and IgG in plasma, Nunc Maxisorb plates
were coated with 10 ng/mL polyclonal rabbit antihuman IgM or
IgG (Sigma-Aldrich) and detected with POD-conjugated don-
key antihuman IgM5Fcl and IgG(Fab)2 fragment, respectively
(Jackson Immuno Research). Standard curves were generated
using puriﬁed human IgM and IgG (both Sigma-Aldrich).
Statistical Analysis
The Kruskal-Wallis test was used to compare distribution of
parameters among different disease categories. Continuous
variables were compared using the Mann-Whitney test and
Wilcoxon rank sum test for unpaired and paired samples, re-
spectively. Correlations among different parameters were ana-
lyzed using the Spearman rank correlation coefﬁcient and
a prediction logistic model to test if the changes in BAFF plasma
concentration could predict if disease was employed. Statistical
analysis was performed using Stata version 11.0, and all tests
were 2-tailed, with P , .05 considered statistically signiﬁcant.
RESULTS
BAFF Plasma Levels Increase With Malaria Disease Severity
We determined the plasma concentration of BAFF in 117 chil-
dren with acute malaria and 54 healthy children. Children with
severe malaria tended to be younger and had higher parasite
load than children with nonsevere or mild malaria, but differ-
ences were not statistically signiﬁcant. They also had signiﬁ-
cantly higher white blood cell (WBC) counts than healthy
children, and all children suffering from acute malaria showed
reduced red blood cell (RBC) counts and hemoglobin concen-
tration (Table 1).
The median plasma concentration of BAFF during acute
malaria was 5.8 ng/mL (interquartile range [IQR] 3.9–9.5),
signiﬁcantly higher than the 2.6 ng/mL (IQR 2.0–3.5) observed
in healthy controls (Mann-Whitney test, P 5 .0001). Interest-
ingly, there was a signiﬁcant progressive increase in BAFF con-
centration with disease severity (Kruskal-Wallis test, P 5 .0001)
(Figure 1). Indeed, children whose BAFF plasma levels were
above the median BAFF plasma level were at a higher risk of
being admitted to hospital either with nonsevere or severe ma-
laria (odds ratio [OR] 5 5.44, P , .0001, v
2 test).
To determine whether the increased plasma concentration of
BAFF was associated with increased levels of IL-10 and IFNc,w e
analyzed their concentration in plasma of all children (Table 1).
As expected, both cytokines were elevated in children suffering
from acute malaria compared with healthy children (Mann-
Whitney test, P 5 .0001, for both cytokines) but did not show
the same progressive increase with disease severity as observed
with BAFF (Kruskal-Wallis, P . .05, for each case). BAFF
plasma levels directly correlated with IFNc (Spearman q 5 0.36,
P 5 .0001) and IL-10 plasma levels (q 5 0.44, P 5 .013).
Parasitemia correlated with the plasma concentration of IL-10
(q 5 0.331, P 5 .002) but not IFNc (q 5 0.042, P 5 .704) or
BAFF (q 5 0.008, P 5 .938).
Expression of BAFF Receptors on B-cell Subsets Is Altered
During Malaria Disease
We determined the expression levels of BAFF-R, TACI, and
BCMA on cryopreserved PBMCs from a subset of 30 children
who returned for their follow-up visit 4 and 16 weeks after an
acute malaria episode, and 9 healthy children. The clinical pa-
rameters and cytokine concentrations in plasma in this subset of
children was comparable to those of the wider group described
above. The percentage of B cells and the absolute number of B
cells in blood were signiﬁcantly increased in children suffering
from acute malaria and during followup compared withhealthy
children (Table 2). During follow up, the plasma concentration
of BAFF in children who suffered from acute malaria returned
to concentrations comparable to those observed in healthy
children, with no signiﬁcant differences between either of the
follow-up visits and healthy children (Figure 2).
The BAFF-R expression on mature B cells was signiﬁcantly
decreased on all B cells from children suffering from malaria
compared with healthy controls (Mann-Whitney test, P 5 .0001)
(Figure 3B), but during follow up, BAFF-R expression levels on
B cells had returned to a level comparable to those of healthy
children. We observed a signiﬁcant increase in the proportion
of BCMA-positive plasma cells during acute disease compared
with healthy children (Mann-Whitney test, P 5 .003) which
returned tolevels similar to thosein healthy children byweeks 4
and 16 of follow up (Figure 3C). The percentage of naive B cells
expressing TACI signiﬁcantly increased during acute disease
compared with healthy children (Mann-Whitney test, P 5 .02;
Figure 3D). Although not signiﬁcant, a similar trend was ob-
served for the proportion of TACI-positive memory B cells
(Mann-Whitney U test, P 5 .07; Figure 3E). Interestingly, the
proportion of TACI-positive B cells continued to increase for
both naive and memory B cells over the follow-up period, and
were maintained at a signiﬁcantly higher level than that observed
in healthy children (Mann-Whitney test, P , .03 for both naive
and memory B cells). We sought to determine if observed
changes in expression of BAFF-R were associated with the plasma
concentration of BAFF. At acute disease, the increase in BAFF
964 d JID 2011:204 (15 September) d Nduati et alplasma levels signiﬁcantly correlated with a reduction of BAFF-R
expression onB cells (q 52 0.52, P5 .003).Interestingly,BAFF-
R expression on B cells was also inversely correlated with the
plasma concentration of IFNc (q 5 –0.56, P5.002)butnotwith
IL-10. It is likely that reduced BAFF-R expression indicated the
rapid activation and differentiation of some B cells into long-
lived plasma cells. Indeed, we observed a signiﬁcant inverse
correlation between BAFF-R expression and the percentage of
BCMA
1 B cells (q 52 0.57, P 5 .002) but not with the per-
centage of TACI
1 memory B cells during acute disease.
Expression of BAFF-R Is Correlated With the Maintenance of
Schizont-Specific Antibodies
Protection against malarial disease is associated with the in-
duction and maintenance of antibody responses to a wide va-
riety of malarial antigens. To determine whether the plasma
concentration of BAFF or BAFF-R expression on B cells was
associated with the induction or maintenance of antibodies, we
measured total and schizont-speciﬁc IgM and IgG antibody
concentrations in plasma. The plasma concentration of total
IgM but not IgG was signiﬁcantly lower in children with acute
malaria at acute disease and at both follow-up time points
compared with healthy controls. As expected, schizont-speciﬁc
IgM responses were signiﬁcantly higher at acute disease and
dropped to levels similar to those observed in healthy children
by week 4 of follow up (Table 3). The concentration of schizont-
speciﬁc IgG was similar to that in healthy children during acute
malaria and at week 4 of follow up, but decreased by week 16 of
follow up.
We further analyzed if the changes observed in BAFF plasma
concentrations or expression of BAFF-R on B cells during acute
disease correlated with total or schizont-speciﬁc antibody re-
sponses during acute disease and follow up. The plasma con-
centrations of total IgG and IgM were not correlated with the
plasma concentration of BAFF or BAFF-R expression on B cells.
By contrast, during acute disease, IgM and IgG schizont-speciﬁc
responses signiﬁcantly correlated with BAFF-R expression on B
cells after normalization of values by log-transformation (Figure
4) and was maintained over the period of follow up, indicating
that maintenance of BAFF-R expression is important for the
maintenance of antigen-speciﬁc antibody responses.
DISCUSSION
Given the role of BAFF in differentiation, survival, and function
of mature B cells, we investigated whether short-lived antibody
responses to malarial antigens observed insomechildrenmay be
due to dysregulation of BAFF or expression of its receptors on B
cells.
Our results demonstrate that BAFF plasma levels increased
during acute malaria but returned to normal levels within
4 weeks of an acute malaria episode. Noticeably, the plasma
concentration of BAFF reﬂected disease severity more closely
than either IFNc or IL-10, independent of parasitemia. Both IL-
10 and IFNc can induce BAFF secretion by myeloid cells, and
their plasma concentration correlated with the plasma concen-
tration of BAFF. BAFF acts on dendritic cells, probably in an
autocrinemanner,andinducestheirmaturationandsecretionof
Table 1. Baseline Parameters of Healthy Controls and Study Population at Presentation With Malaria
Parameters
Healthy children
an 5 54
Mild malaria
a
n 5 47
Nonsevere admissions
a
n 5 23
Severe admissions
a
n 5 47
Age (months) 58.6 (22.5–87.9) 43.1 (27.8–67.9) 47.0 (33.5–55.9) 38.2 (25.9–50.3)
Parasites (10
3/lL) . 30.4 (27.5–145.5) 200.0 (116.0–439.4) 204.1 (113.6–331.5)
WBC count (10
3/lL) 6.8 (5.7–9.8) 7 (4.6–9.5) 9.1 (5.6–12.9) 9.8 (7.7–11.9)
b
RBC count 10
6/lL 4.5 (4.1–4.9) 3.5 (2.5–4.3)
b 3.9 (3.5–4.3)
b 3.4 (2.5–3.9)
b
Hb conc. (mg/dL) 10.6 (9.9–11.1) 7.6 (6.3–10)
b 9.2 (7.2–10.4)
b 7.3 (5.8–9.4)
b
IL-10 (pg/mL) 0.67 (0–14.1) 511.0 (156–1298)
b 746.3 (269–1867)
b 908.9 (268–1412)
b
IFNc (pg/mL) 0 (0–3.8) 8.1 (0–27.4)
b 8.4 (0–110)
b 10.7 (0–51.9)
b
NOTE. Hb, hemoglobin; IFNc, interferon c; IL-10, interleukin 10; RBC, red blood cells; WBC: white blood cells.
a Values are presented as median (25th and 75th percentile).
b P , .05 Mann-Whitney U tests.
Figure 1. The plasma concentration of BAFF increases with increasing
disease severity in children suffering from acute malaria. Box-and-
whisker plot of the median BAFF plasma concentration in healthy children
and those suffering from either mild, nonsevere, or severe, life-
threatening malaria. Boxes show the 25th and 75th percentile, and
whiskers present the 5th and 95th percentile. Circles denote outliers.
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1 (Th1) T-cell responses [35]. Thus, BAFF may play an im-
portant role in the inﬂammatory response and contribute to
inﬂammation-associated immunopathology during acute malaria.
The plasma concentration of BAFF is upregulated in
many autoimmune conditions [23–25] and in some infections
that present with polyclonal activation of B cells, hyper-
gammaglobulinemia, and autoimmune-like syndromes [26, 27].
Interestingly, we did not observe a correlation between the
plasma concentration of BAFF and total or schizont-speciﬁc
antibody concentrations during acute disease or during follow
up. However, several studies reported overall higher levels of
auto-antibodies in people living in malaria-endemic areas and
linked this observation to repeated immune activation with
frequent malaria episodes [36]. It seems possible that repeatedly
elevated levels of BAFF during acute malaria episodes contribute
to a rescue of auto-reactive B cells in people living in malaria-
endemic areas [37–39].
BAFF is detected in plasma of all individuals and constitu-
tively occupies BAFF-R expressed on all resting mature B cells.
Upon B-cell receptor (BCR) activation in a T-cell–dependent
manner, BAFF enhanced B-cell proliferation, differentiation into
plasma cells, and the secretion of immunoglobulin [19, 21]. In
contrast, activation of B cells in a T-cell-independent manner in
the presence of BAFF attenuates differentiation to plasma cells
[40]. B cells that differentiate into plasma cells downregulate
expression of BAFF-R and upregulate expression of BCMA,
a BAFF receptor exclusively expressed on long-lived plasma cells
[21, 41]. The role of TACI is less well understood. TACI is
expressed on a proportion of MBCs and also an early marker of
B-cell activation [41]. Expression of TACI is upregulated upon
engagementofToll-likereceptor9(TLR9),CD40,ortheBCRon
B cells, and some studies have suggested that it is indispensable
for the differentiation of B cells into plasma cells and class switch
recombination in response to T-independent antigens [42, 43]
and to a lesser extend for T-dependent antigens [44, 45].
In our study, all peripheral B cells from healthy children ex-
pressed BAFF-R in line with previous reports [41, 46]. However,
BAFF-R expression wassigniﬁcantly downregulatedon all B cells
of children during acute malaria. The reduction in BAFF-R ex-
pression was transient, and all children exhibited normal ex-
pression levels of BAFF-R 4 weeks and 4 months after the acute
malaria episode. Kumsiri et al. [30]r e p o r t e dt h a tB A F F - Re x -
pression is upregulated on B cells in vitro in response to he-
mozoin or P. falciparum–soluble antigen. These observations are
not necessarily contradictory, since children with acute malaria
will have been infected with asexual blood-stage parasites for
several days before developing clinical symptoms, and BAFF-R
expression on B cells might increase during the early phase of
blood stage infection. It is likely that B-cell activation during
acute infection resulted in reduced BAFF-R expression due to
Table 2. Baseline Characteristics of the Subset of Children Who Returned for Follow Up
Parameters
Healthy children
a
n 5 9
Acute
a
n 5 30
Week 4
a
n 5 30
Week 16
a
n 5 30
Age (months) 84.7 (52.9–100.3) 51.8 (41.1–65.9) 52.8 (42.8–66.9) 55.8 (45.8–69.9)
WBC count (10
3/lL) 6.8 (5.7–9.8) 8.05 (5.1–10.6) 8.1 (6.7–9.4) 8.6 (7.4–9.8)
RBC count (10
6/lL) 4.7 (4.2–5.4) 3.5 (2.5–4.1)
b 4.4 (4.1–4.9) 4.7 (4.4–5.2)
Hb conc. (mg/dL) 11.0 (10–11.2) 7.8 (6.0–9.2)
b 10.3 (9.8–11.3) 10.5 (9.8–11.9)
B cells (% PBMC) 8.9 (7.7–12.8) 19 (13.2–26.5)
b 17.7 (12.8–21.9)
b 18 (13.5–22)
b
B cells (10
3/lL) 0.28 (0.21–0.35) 1.8 (0.7–2.8)
b 1.2 (0.95–2.0)
b 1.3 (0.9–2.0)
b
BAFF (ng/mL) 3.5 (3.1–3.9) 5 (4.1–9.1)
b 3.3 (2.6–4.2) 3.5 (2.3–4.0)
IL-10 (pg/mL) 0 721 (491–1368)
b ..
IFNc (pg/mL) 0 4.7 (0–14.9)
b ..
NOTE. BAFF, B-cell activating factor; Hb, hemoglobin; IFNc, interferon c; IL-10, interleukin 10; PBMC, peripheral blood mononuclear cell; RBC, red blood cell;
WBC, white blood cell.
a Values are presented as median (25th and 75th percentile).
b P , .05 Mann-Whitney U tests.
Figure 2. The plasma concentration of BAFF is increased only during
acute disease. Median BAFF plasma concentration determined in healthy
children and children suffering from acute malaria (acute) and 4 weeks
(week 4) and 16 weeks (week 16) after the acute episode. Boxes show the
25th and 75th percentile, and whiskers present the 5th and 95th
percentile. Circles denote outliers.
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BCMA expression, at least for a proportion of B cells [41]. In-
deed, we observed a signiﬁcant inverse correlation between
BAFF-R expression and the proportion of BCMA-positive
B cells, indicating thatlong-livedplasma cellsareinducedduring
an acute malaria episode. However, only a small proportion
of peripheral blood B cells differentiated into plasma cells
whereas the reduction in BAFF-R expression was observed on
the entire population of B cells, suggesting either internalization
or shedding of BAFF-R in the presence of high and sustained
levels of BAFF [40], as has been described for patients with
Sjogren’s syndrome and systemic lupus erythematosus [47].
Whether the reduction of BAFF-R expression on B cells during
acute malaria is a normal homeostatic response to high con-
centrations of BAFF or indicative of a pathological mechanism
or both requires further investigation. However, those children
suffering from acute malaria who maintained the highest ex-
pression levels of BAFF-R on B cells showed signiﬁcantly higher
Figure 3. Expression of BAFF receptors on B cells in children with acute malaria and during follow up. CD19-positive B cells were identified in the
lymphocyte gate. A, Representative dot plot of BAFF-R-positive CD19-positive B cells, BCMA-positive CD19-low, and TACI-positive naive (CD27-) or
memory B cells (CD27
1) of 1 healthy child and 1 child suffering from acute malaria. Box plot of MFI of BAFF-R B, the proportion of BCMA-positive CD19-
low B cells C, and TACI-positive naive D, and memory E B cells in healthy children and children with malaria during acute disease and week 4 and week
16 follow up. Boxes show the 25th and 75th percentile, and whiskers present the 5th and 95th percentile. Circles denote outliers.
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malaria episode, suggesting that the overall reduction of BAFF-R
expression on all B cells renders at least a proportion of them
insensitiveto theactionofBAFF.Inthiscontext, it isnoteworthy
that TLR9 agonists such as CpG reduces the expression of BAFF-
R but increases the expression of TACI on B cells [41]. In
the presence of high concentrations of BAFF, TLR9 agonists
attenuate the differentiation of memory B cells into antibody-
secreting plasma cells [40]. Interestingly, the percentage of
TACI-positive naive and memory B cells increased during acute
malaria and was maintained over the entire 4 months of follow
up. The proportion of TACI-positive naive or memory B cells
and the plasma concentration of BAFF or reduced expression of
the BAFF-R in children suffering from acute malaria did not
correlate, suggesting that the induction of TACI on B cells was
independently regulated. Parasite DNA complexed by poly-
cationic carriers or hemozoin is a potent TLR9 agonist [48, 49],
althoughthelatterremainscontroversial.WhetherparasiteDNA
activates Bcells directlyhasnot beeninvestigated. Atleast during
time of acute disease, when the concentration of BAFF is high,
DNA from parasites may provide a constant trigger for TLR9-
induced TACI expression on B cells and attenuate their differ-
entiation into antibody-secreting plasma cells.
The effect of blockade of BAFF by a monoclonal anti-BAFF
IgG and BAFF-R Ig-fusion protein have been tested in clinical
trials for treatment of systemic lupus erythematosus (SLE) and
rheumatoidarthritis (RA), and ameliorated disease activity[50].
Blocking BAFF during acute severe malarial disease may in-
terrupt positive feedback between IFNc and BAFF and thus
reduce inﬂammation while facilitating the induction of long-
lived plasma cells. However,a better understanding of the action
of BAFF during acute malaria is required before its therapeutic
use can be considered.
In summary, we show that the concentration of BAFF is in-
creased during acute malaria and reﬂects disease severity. In
addition, we observed dynamic regulation of the expression of
the 3 BAFF receptors (BAFF-R, BCMA, and TACI) on B cells
during acute malaria and follow up. It is likely that a proportion
of B cells received T cell help and differentiated into BCMA-
expressing plasma cells. However, the reduction of the BAFF-R
on all peripheral blood B cells and the parallel increase of TACI-
positive B cells indicated that the regulation of BAFF receptor
expression during B-cell differentiation may be altered, ren-
dering a proportion of B cells insensitive to BAFF. Further
studies are necessary to identify whether parasite DNA could
engage TLR9 expressed on activated MBCs and inhibit their
differentiation to plasma cells in the presence of BAFF.
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Table 3. Total and Schizont-Specific IgM and IgG Schizont in Plasma
Healthy children
a
n 5 8
Acute
a
n 5 30
Week 4
a
n 5 30
Week 16
a
n 5 30
IgM (ng/mL) 253 (182–278) 158 (94–257)
b 144 (41–216)
b 168 (57–201)
b
IgG (ng/mL) 1051 (861–1061) 966 (905–1090) 980 (870–1031) 932 (881–995)
IgM schizont (OD) 0.06 (0.05–0.13) 0.16 (0.09–0.34)
b 0.08 (0.06–0.17) 0.05 (0.03–0.11)
IgG schizont (OD) 0.21 (0.06–0.37) 0.17 (0.10–0.38) 0.21 (0.11–0.34) 0.10 (0.04–0.25)
NOTE. IgG, immunoglobin G; IgM, immunoglobulin M; OD, optical density.
a Values are presented as median (25th and 75th percentile).
b P , .05 Mann-Whitney U tests.
Figure 4. The expression of BAFF-R on B cells correlates with schizont-
specific IgM and IgG during acute malaria and follow up. Shown are
scatter plots of log-transformed OD values for schizont-specific IgM and
IgG during acute malaria and week 4 and week 16 follow up. OD, optical
density; GM, geometric mean.
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